Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Journal of Neuro-Oncology Pub Date : 2024-09-01 Epub Date: 2024-06-06 DOI:10.1007/s11060-024-04722-2

Adeline Zinsz, Shamimeh Ahrari, Jason Becker, Ali Mortada, Veronique Roch, Louis Doriat, Matthieu Santi, Marie Blonski, Luc Taillandier, Timothée Zaragori, Antoine Verger

{"title":"Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.","authors":"Adeline Zinsz, Shamimeh Ahrari, Jason Becker, Ali Mortada, Veronique Roch, Louis Doriat, Matthieu Santi, Marie Blonski, Luc Taillandier, Timothée Zaragori, Antoine Verger","doi":"10.1007/s11060-024-04722-2","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to evaluate the prognostic performance of amino-acid PET in high-grade gliomas (HGG) patients at the time of temozolomide (TMZ) treatment discontinuation, after the Stupp protocol.Methods: The analysis included consecutive HGG patients with dynamic [18F]FDOPA PET imaging within 3 months of the end of TMZ therapy, post-Stupp protocol. Static and dynamic PET parameters, responses to RANO criteria for MRI and clinical and histo-molecular factors were correlated to progression-free (PFS).Results: Thirty-two patients (59.4 [54.0;67.6] years old, 13 (41%) women) were included. Static PET parameters peak tumor-to-background ratio and metabolic tumor volume (respective thresholds of 1.9 and 1.5 mL) showed the best 84% accuracies for predicting PFS at 6 months (p = 0.02). These static PET parameters were also independent predictor of PFS in multivariate analysis (p ≤ 0.05).Conclusion: In HGG patients having undergone a Stupp protocol, the absence of significant PET uptake after TMZ constitutes a favorable prognostic factor.","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341581/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-024-04722-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to evaluate the prognostic performance of amino-acid PET in high-grade gliomas (HGG) patients at the time of temozolomide (TMZ) treatment discontinuation, after the Stupp protocol.

Methods: The analysis included consecutive HGG patients with dynamic [18F]FDOPA PET imaging within 3 months of the end of TMZ therapy, post-Stupp protocol. Static and dynamic PET parameters, responses to RANO criteria for MRI and clinical and histo-molecular factors were correlated to progression-free (PFS).

Results: Thirty-two patients (59.4 [54.0;67.6] years old, 13 (41%) women) were included. Static PET parameters peak tumor-to-background ratio and metabolic tumor volume (respective thresholds of 1.9 and 1.5 mL) showed the best 84% accuracies for predicting PFS at 6 months (p = 0.02). These static PET parameters were also independent predictor of PFS in multivariate analysis (p ≤ 0.05).

Conclusion: In HGG patients having undergone a Stupp protocol, the absence of significant PET uptake after TMZ constitutes a favorable prognostic factor.

Abstract Image

查看原文本刊更多论文

将氨基酸正电子发射计算机断层扫描作为高级别胶质瘤患者接受斯托普方案后替莫唑胺治疗后的预后工具。

目的：本研究旨在评估在Stupp方案后，替莫唑胺（TMZ）治疗终止时氨基酸PET在高级别胶质瘤（HGG）患者中的预后表现：分析对象包括Stupp方案后TMZ治疗结束后3个月内进行动态[18F]FDOPA PET成像的连续HGG患者。静态和动态 PET 参数、对 MRI RANO 标准的反应以及临床和组织分子因素与无进展（PFS）相关：共纳入 32 名患者（59.4 [54.0;67.6] 岁，13 名女性（41%））。静态 PET 参数肿瘤与背景的峰值比和代谢肿瘤体积（阈值分别为 1.9 mL 和 1.5 mL）在预测 6 个月的无进展生存期方面显示出 84% 的最佳准确率（p = 0.02）。在多变量分析中，这些静态 PET 参数也是预测 PFS 的独立指标（p ≤ 0.05）：在接受了Stupp方案治疗的HGG患者中，TMZ治疗后PET无明显摄取是一个有利的预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuro-Oncology 医学-临床神经学

CiteScore

6.60

自引率

7.70%

发文量

277

审稿时长

3.3 months

期刊介绍： The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.